LifeSciences BC > News > Industry News > 2015 > LifeSciences BC Responds to CADTH Report on Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

October 29, 2015
Brian O’Rourke, President and Chief Executive Officer,
Canadian Agency for Drugs & Technologies in Health
865 Carling Ave.,
Ottawa, ON K1S 5S8

Re.: Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

Dear Mr. O’Rourke:

LifeSciences BC is a member driven organization which supports and represents the interests of the human life science community in British Columbia. We are a not-for-profit association sustained by our membership which includes: Academia, R&D, Health Foundations and Organizations, SME’s, bio pharmaceuticals and bioinformatics along with other non-profit life science bodies located here and around the globe.

I write to you today on behalf of our membership who have critical concerns regarding the recent Anti-VEGF Therapeutic Review Draft Science Report on Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions. We are aware and have been in contact with, both Canada’s Research-Based Pharmaceutical Companies (Rx&D) and BIOTECanada, who have undertaken to submit a response on behalf of researched based pharmaceutical companies.

LifeSciences BC fully supports and endorses the consultation response from Rx&D and BIOTECanada and we request that the recommendations identified in their considered response, be addressed in a timely and regulatory efficient manner.

Sincerely,
Paul Drohan,
President & CEO,
LifeSciences BC